Hycodan is classified under which schedule?

Hycodan, a medication that contains hydrocodone combined with homatropine methylbromide, is classified as a Schedule III controlled substance under the Controlled Substances Act. This classification is based on its potential for abuse, which is less than that of drugs in Schedule I and Schedule II but more than drugs in Schedule IV.

Schedule III drugs have a moderate potential for physical and psychological dependence. The inclusion of hydrocodone, an opioid, in Hycodan contributes to its classification due to hydrocodone's recognized potential for abuse and addiction, albeit to a lesser degree than stronger opioids classified under Schedule II. This classification reflects the regulatory stance that, while Hycodan is useful in therapeutic contexts (such as for cough suppression), it also requires monitoring and control due to the risks associated with opioid medications.

In contrast, the schedules listed in the other choices—Schedule I (no accepted medical use and high potential for abuse), Schedule II (high potential for abuse with severe psychological or physical dependence), and Schedule IV (lower potential for abuse relative to Schedule III)—reflect different levels of control and risk associated with various substances. The classification of Hycodan in Schedule III highlights the balance between its medical benefits and